How to read this dashboard
This tool runs a before / after budget impact analysis over a 5-year horizon. The "before" is the Status Quo treatment mix for HMB in the selected country; the "after" is the same population redistributed once you raise H-IUD uptake. Every KPI, table, and chart below shows the incremental difference between those two scenarios.
Positive cost deltas = added spend; negative = savings. Positive clinical deltas (DALYs averted, HMB resolved, anemia avoided) = health gains. Monetary values are shown in LCU or in 2025 constant USD. LCU = Local Currency Unit.
| Arm | MS₀ | MS₁ | ΔMS | Patients shifted | Cost SQ | Cost Int (Comm) | Cost Int (Non-Comm) | ΔCost |
|---|---|---|---|---|---|---|---|---|
| H-IUD | 0.0% | 0.0% | +0.0% | 0 | 0 LCU | 0 LCU | 0 LCU | 0 LCU |
| Non-Surgical | 20.2% | 20.2% | +0.0% | 0 | 39.73B LCU | 25.91B LCU | 13.83B LCU | 0 LCU |
| Surgical | 5.4% | 5.4% | +0.0% | 0 | 22.96B LCU | 19.20B LCU | 3.76B LCU | 0 LCU |
| Untreated | 74.4% | 74.4% | +0.0% | 0 | 32.67B LCU | 6.44B LCU | 26.23B LCU | 0 LCU |
| Grand Total | — | — | — | 0 | 95.36B LCU | 51.55B LCU | 43.81B LCU | 0 LCU |
Net population health gain from women transitioned to H-IUD from each baseline arm. Reflects a marginal change of (Dᵢ − D_H) DALYs per woman transitioned.
Estimated population-level prevalence of HMB and Anemia, reflecting the net clinical impact of shifting treatment distributions across the cohort.
Each arm shows two stacked bars: Status Quo (grey) and Intervention (orange), split into Commodity (solid) and Non-Commodity (lighter shade).
Each colored dot represents a scenario where that single treatment covers 100% of the HMB population — its total 5-year cost vs. total 5-year DALYs averted (higher DALYs averted and lower cost are better; the shaded top-left region marks Efficient Allocation). The dashed line traces the non-dominated frontier (Untreated → H-IUD → Surgical); strategies off this line are dominated. The dark dot is the population average under the current coverage mix.